Abacavir has replaced stavudine in antiretroviral therapy (ART) regimens because it has largely been phased out as a result of toxicity concerns; this loss has reduced further the already-limited drug options for children. Few data regarding virologic and metabolic outcomes among children who undergo substitution of stavudine exist. We evaluated the effects of preemptive substitution of abacavir for stavudine in children initially without lipodystrophy and virally suppressed on a stavudine-containing regimen.
These stavudine-related body fat and metabolic alterations led to the gradual phasing out of the drug for adults, adolescents, and children. Following the World Health Organization recommendations to phase out the use of stavudine [16] , the South African 2010 Paediatric HIV Treatment Guidelines replaced stavudine with abacavir as part of the first-line initiation regimen. Until recently, the efficacy of abacavir in children had not been well established [17] . Removing stavudine as a treatment option is of greater consequence for children than adults. Therapeutic options for children are quite limited (not all licensed antiretroviral agents are available in formulations suitable for children), and dosing and efficacy have not been established for pediatric use. Tenofovir, the drug of choice to replace stavudine in adult regimens, carries its own toxicity concerns when used in children [18] .
The purpose of this trial was to evaluate the substitution of abacavir for stavudine in virally suppressed prepubescent children for whom no clinical evidence of lipodystrophy exists. At the time the study was conducted, programmatic data suggested a temporal trend with worse virological outcomes in children initiated on treatment coincident with practice changes in which abacavir replaced stavudine in first-line regimens in South Africa [19, 20] . Thus, specific aims of this study included comparing rates of viral suppression and differences in regional body fat distribution and lipid profiles. At the time this trial was initiated, local guidelines advised retaining stavudine in virally suppressed children who were not experiencing adverse drug effects [21] . The trial was completed by the time the 2013 and revised 2014 South African guidelines advocated switching all virally suppressed children using stavudine as part of their ART regimen to abacavir [22, 23] . The results of our study provide randomized clinical trial data to help inform these guideline changes.
METHODS

Study Design
This study was a nonblinded randomized trial of substitution of abacavir for stavudine among children who were virally suppressed and on a stavudine-containing regimen. All children were coenrolled in a larger randomized trial that evaluated a switch to efavirenz-based ART in nevirapine prophylaxis-exposed children [24] . Eligibility criteria for the larger trial included an age of ≥36 months, exposure to perinatal nevirapine prophylaxis, and viral suppression (HIV RNA, <50 copies/mL) while on a ritonavir-boosted lopinavir (LPV/r)-based regimen for at least 12 months. The study was conducted at Rahima Moosa Mother and Child Hospital in Johannesburg, South Africa, from June 2010 to December 2013. At enrollment onto the larger trial, children were screened for eligibility for the abacavir-substitution trial. Eligibility criteria included current receipt of stavudine as part of an ART regimen and no contraindications for taking either stavudine or abacavir. Children who presented with evidence of lipodystrophy as detected by the study clinicians were not eligible but were included in the larger trial.
Eligible children were assigned randomly to remain on their stavudine regimen (1 mg/kg per dose, twice daily) or to switch to abacavir (8 mg/kg per dose, twice daily). Lamivudine (4 mg/ kg per dose, twice daily) was used for all children. Children were not tested for the HLA B*5701 allele before switching to abacavir because of the low prevalence of this allele in the South African population [25] (testing is not prescribed in the South African pediatric HIV treatment guidelines [23] ). Eight weeks after the initial random assignment, the children were assigned randomly to either switch to efavirenz or continue on the initial LPV/r-based regimen. Random assignments were concealed in opaque envelopes opened on site at the time of randomization. Assignments were generated by the study statistician, who used a permuted block design and block sizes between 8 and 12. The 2 randomizations were independent.
The study was approved by the institutional review boards of the University of the Witwatersrand (Johannesburg, South Africa) and Columbia University (New York, New York). Signed informed consent was provided by each child's legal guardian.
Outcomes
Children were followed up at 4, 8, 12, 16, 24, 32, 40, 48 , and 56 weeks after their random assignment. At each study visit, their body weight (in kilograms) and height (in centimeters) were measured by a digital scale and stadiometer, respectively. Weight-for-age z scores (WAZs) and height-for-age z scores (HAZs) were determined by using World Health Organization growth standards [26] . Underweight was defined as a WAZ of less than −2 and stunting as a HAZ of less than −2.
Additional anthropometric measurements, including limb and trunk circumferences and skinfold thicknesses, were measured by trained study physicians at the baseline visit and again 8 and 48 weeks after randomization. Circumferences were measured using a flexible tape measure with a spring attachment and included the mid-upper arm, mid-waist, maximum hip, and mid-thigh. Skinfold thicknesses, consistently taken on the right-hand side of the body, were measured with a Harpendon calliper (Baty International, Burgess Hill, United Kingdom) at the bicep, tricep, subscapular, suprailiac, umbilical, and midthigh folds. The total sum of skinfolds as an estimation of total fat was calculated by adding all these skinfold measurements. Regional fat distribution was described using regional fat proportions of total fat and trunk/extremity fat ratios as previously described [27] . Body fat percentage was estimated by measuring total body resistance using single-frequency bioimpedance analysis (Quantum II [RJL Systems, Clinton Township, Michigan]) [28] .
At each visit, the study physicians performed evaluations to identify clinical lipodystrophy (definite, possible, or no). Signs of lipodystrophy included both lipoatrophy (sunken cheeks, skinny limbs, and buttocks wasting) and lipohypertrophy (dorsal cervical enlargement and increased abdominal girth). On the basis of the lipodystrophy assessments obtained at all scheduled and unscheduled postrandomization visits, each child was assigned to 1 of the following 4 final categories: definite lipodystrophy (≥2 definite diagnoses), probable lipodystrophy (≥2 possible diagnoses), possible lipodystrophy (only 1 definite or 1 possible diagnosis), or no lipodystrophy.
Each child's CD4 T-cell percentage was determined at baseline and 32 and 56 weeks after randomization with a flow analyzer (Beckman Coulter, Indianapolis, Indiana). Each child's plasma HIV RNA quantity (in copies/milliliter) was measured at baseline and 8, 12, 16, 24, 32, and 56 weeks after randomization by using the AmpliPrep/COBAS TaqMan HIV-1 2.0 test (Roche, Branchburg, New Jersey). Fasting blood lipid levels (in milligrams per deciliter), including total cholesterol, triglyceride, high-density lipoprotein, and low-density lipoprotein (LDL), and insulin and C-reactive protein levels were measured at baseline and 8 and 48 weeks after randomization using the COBAS INTEGRA 400 (Roche). Venous blood glucose levels were measured with a handheld glucometer. Children were assessed also for drug hypersensitivity at each visit.
Statistical Analysis
Intent-to-treat analyses were conducted using available follow-up data. The cumulative probability of viral rebound (defined as 1 or more HIV type 1 [HIV-1] RNA measurements of >50 copies/mL) and viral failure (defined as 2 or more HIV-1 RNA measurements of >1000 copies/mL) was calculated using Kaplan-Meier methods; the randomization groups were compared using log-rank tests. Other outcomes were compared across groups using the t test for continuous variables or the χ 2 or Fisher exact test for categorical variables. Analyses were conducted using SAS 9.4 (SAS Institute, Inc, Cary, North Carolina). All statistical tests were 2-sided, and a P value of <.05 was considered statistically significant.
RESULTS
Of the 300 children enrolled in the larger trial, 213 (71%) were eligible and enrolled for random assignment to have stavudine substituted with abacavir. We randomly assigned 106 children to remain on stavudine and 107 to switch to abacavir. The 2 randomization groups did not differ significantly in terms of overall characteristics, pre-ART measurements, or baseline measurements (Table 1) . Additional demographic characteristics, including caregiver education, caregiver employment status, and household characteristics, did not differ between randomization groups (data not shown). The 87 children not eligible for random assignment differed from those who were randomly assigned in that they were younger (mean age, 3.9 vs 4.2 years, respectively; P = .006) and had worse growth, with a lower mean pretreatment WAZ (−2.46 ± 1.7; P = .072) and a mean WAZ and HAZ that were also lower at baseline (−1.05 ± 0.8 [P = .003] and −1.55 ± 0.9 [P = .043], respectively) ( Table 1) .
There were no deaths, and 292 (97.3%) of the 300 children completed the 56 weeks of study ( Figure 1 ). Of the 8 children not retained through the end of the study, 4 were in the stavudine group, 3 were in the abacavir group, and 1 was not randomly assigned. Discontinuations were a result of relocations out of the area and had no apparent link to the study. Among the 102 children randomly assigned to continue taking stavudine who were retained in the study, 22 (21.6%) were switched to abacavir during study follow-up, including 16 children with definite, 4 with probable, and 1 with possible lipodystrophy, and 1 was switched for an unknown reason. All children randomly assigned to abacavir remained on the drug through the end of the study (Figure 1 ). There were no cases of abacavir hypersensitivity. Of the 87 children not eligible for random assignment, 16 had been initiated on an abacavir-containing regimen (1 had been treated with stavudine during the course of therapy), 59 had been initiated on a stavudine-containing regimen but had switched to abacavir at or before baseline, and 12 were on a zidovudine-containing regimen at baseline (3 had been treated previously with stavudine).
The probabilities of viral rebound to >50 copies/mL after 56 weeks were similar in the stavudine (.295) and abacavir (.240) groups (P = .233). The probabilities of confirmed viral failure (>1000 copies/mL) after 56 weeks also were similar in the stavudine (.033) and abacavir (.019) groups (P = .608) (Supplementary Table 1 ). When examined from a repeat cross-sectional perspective, the proportion of children with a viral load of >50 copies/mL was not significantly different at any follow-up time point (data not shown). Both groups remained within the reference range for CD4 percentage and count throughout the study. The mean CD4 percentages did not differ significantly between groups either 32 or 56 weeks after randomization. We also found no differences in the rate of change in CD4 percentages or counts (Supplementary Table 1) .
We found no significant differences in WAZs or HAZs or in the proportions of children who were underweight or stunted between randomization groups at any of the follow-up visits (data not shown). The mean WAZs 56 weeks after randomization were −0.72 ± 1.0 (stavudine group) and −0.72 ± 1.0 (abacavir group) (P = .962), and the mean HAZs were −1.18 ± 1.0 (stavudine group) and −1.21 ± 1.0 (abacavir group) (P = .851) (Supplementary Table 1 ). We found no differences between the groups in WAZ or HAZ changes from baseline to 56 weeks after randomization.
Fasting lipid values at baseline and 8 and 48 weeks after randomization are shown in Supplementary Table 2 . At baseline, metabolic measurements were similar across the groups. Eight weeks after randomization, the proportion of children with an elevated LDL level was higher in the abacavir group than in the stavudine group (25.2% vs 10.8%, respectively; P = .023), and the proportion of children with an elevated C-reactive protein level was higher in the stavudine group than in the abacavir group (47.0% vs 31.7%, respectively; P = .026). However, 56 weeks after randomization, these differences no longer remained.
These analyses were repeated separately for those randomly assigned to LPV/r and efavirenz, and the findings were consistent with what we reported earlier.
The nonrandomized group had viral loads and CD4 results similar to those of the randomized group. The nonrandomized group continued to demonstrate poorer growth than the randomized group, with a mean WAZ 56 weeks after randomization of −0.98 ± 0.8 (P = .021) and a mean change in WAZ from the randomization time point of 0.07 ± 0.3 (P = .002). The mean HAZ 56 weeks after randomization revealed a more marked improvement (−1.38 ± 0.9), which did not differ significantly from that of the randomized group (P = .140). Compared to the randomized group, a higher proportion of children (32.2%) had an elevated triglyceride levels at baseline (P = .0002). This difference persisted 8 weeks after randomization (P = .032) but normalized by 56 weeks after randomization (P = .082).
Total fat estimated by the total sum of skinfolds and bioimpedance analysis did not differ between the stavudine and abacavir groups 48 weeks after randomization. However, regional fat proportions for the trunk and leg, and the trunk/ leg-skinfold ratios, revealed relatively more fat in the trunk (proportion of trunk-skinfold ratios relative to total skinfold sum, mean ± SD, 0.456 ± 0.05 vs 0.444 ± 0.05 [P = .042] for the stavudine and abacavir groups, respectively) and less fat in the leg (proportion of leg-skinfold ratios relative to total skinfold sum, mean ± SD, 0.230 ± 0.03 vs 0.243 ± 0.03 [P = .006] for the stavudine and abacavir groups, respectively) in the stavudine than in the abacavir group (Table 2 ). These differences remained statistically significant after we adjusted for baseline differences, which included relatively less leg fat in the group randomly assigned to remain on stavudine. When stratified according to the LPV/r and efavirenz randomizations, these significant differences with more fat in the trunk and less in the leg in the stavudine group than in the abacavir group were confined to the efavirenz arm, although the interaction term was not statistically significant (data not shown).
In follow-up through 56 weeks, 17 (16%) of the children in the stavudine group had a definite clinical lipodystrophy diagnosis compared to just 4.7% of children in the abacavir group (P = .006) ( Table 2) . Of the 17 children in the stavudine group, Values shown are number (%) or mean ± SD unless indicated otherwise.
16 had their treatment regimen adjusted to discontinue stavudine and start abacavir. A greater proportion of children in the stavudine group had a definite clinical lipodystrophy diagnosis than those in the abacavir group within those randomly assigned to LPV/r (20.8 vs 6.3%, repectively; P = .04) and efavirenz (11.3 vs 3.5%, repectively; P = .198).
Throughout the follow-up period, lipodystrophy was assessed also in children not eligible for random assignment (n = 87). This group was heterogeneous and included children who had either never been on stavudine or who had been switched off it because of an adverse experience. Of 15 children who had initiated abacavir as part of their primary regimen and were still on it at baseline, 1 (6.7%) had definite lipodystrophy during the follow-up period. Of 9 children who were on zidovudine at baseline and who had not been exposed to stavudine, 1 (11.1%) had definite lipodystrophy during the follow-up period. Of 4 children who had stavudine exposure but were taking abacavir or zidovudine at baseline, 2 had definite lipodystrophy during the follow-up period. For the 59 children who had been treated with stavudine but who had switched to abacavir at or before baseline, we assessed clearance of the condition, defined as no evidence of lipodystrophy in the last 2 visits. Lipodystrophy seemed to have resolved in 19 (32.2%) children by the end of the follow-up period. The trunk/arm-skinfold ratio decreased between baseline and the end of the study (P = .032), but the trunk/leg-skinfold ratios remained similar (P = .122).
DISCUSSION
In this randomized clinical trial that involved young South African children infected perinatally with HIV, we assessed changes in virologic and immunologic measures and body composition and lipid profiles after substituting abacavir for stavudine in virally suppressed children without clinical evidence of lipodystrophy. Abacavir substitution did not compromise viral suppression, and we observed no untoward effects on growth or immunological response or abacavir hypersensitivity reactions. Substitution with abacavir was associated with a significant reduction in clinical signs of lipodystrophy and relative reductions in central adiposity and increased leg fat. However, no improvement in the lipid profiles was observed. Our results provide clinical trial data to support current recommendations for replacing stavudine with abacavir in combination ART for HIV-infected children.
Lipodystrophy can be a stigmatizing and disfiguring condition that adversely affects ART adherence [29] .
Given the immense importance of body image to the adolescent psyche, lipodystrophy can be particularly troublesome with respect to ART adherence among adolescents [30] . Thus, our finding of less clinically apparent lipodystropy, and improved regional fat distribution in the abacavir-substitution group despite an average of 3 years' previous stavudine exposure, is reassuring. However, a limitation of our trial is that it was not blinded, and clinician expectation could have biased the results in favor of abacavir. To reduce the risk of bias, lipodystrophy was diagnosed by the study physicians following standardized criteria, and we confined our analyses to those with a "confirmed" clinical diagnosis at 2 separate study visits. Clinical diagnoses were reasonably consistent over time and across study physicians (data not shown). In addition, these clinical diagnoses were consistent with more objective anthropometric data, including circumferences and skinfold measurements. Thus, our results strongly implicate stavudine as an avoidable risk factor for the development of lipodystrophy. However, in the CHAPAS-3 trial, clinically evident lipodystrophy was not noted in children randomly assigned to the stavudine group, and this finding was attributed to the young age of the cohort (mean, 2.6 years), the relatively short follow-up period (mean, 2.3 years), the absence of a protease inhibitor (PI) in the ART regimen, and that the majority of the children were ART naive before their study participation [31] .
Our trial was nested in a larger trial that switched children initially suppressed with LPV/r to efavirenz or maintained them on LPV/r [24] . Although stavudine was associated with more lipodystrophy in both the efavirenz and LPV/r groups, our data suggest that more lipodystrophy occurred in those maintained on LPV/r and stavudine than in those randomized to EFV and stavudine. Adverse effects of ritonavir on growth have been reported [32] . When compared to patients on an integrase inhibitor-containing regimen, those who use a ritonavir-boosted PI regimen experience significant increases in visceral and total adipose tissue [33] . Similar effects caused by LPV/r in our population might have masked the benefits of abacavir. Treatment with LPV/r and stavudine for more than 3 years before this trial also might explain the relatively high rates of lipodystrophy apparent at baseline in the children not eligible for random assignment.
Changing an antiretroviral regimen to exclude drugs responsible for lipodystrophy can arrest the fat-redistribution process and normalize physiological fat accrual, but features of lipodystrophy might never resolve completely [34, 35] . Our trial was designed for children who had not yet developed clinical signs of lipodystrophy, and the results provide reassurance that preemptive substitution might prevent this complication. Among the children in our study who had lipodystrophy at baseline and who therefore were not eligible for random assignment but were switched to abacavir on clinical grounds, approximately one-third of them were free of lipodystrophy at the end of the study 56 weeks later. Longer-term follow-up will be necessary to determine whether further improvements occur over time. In other studies, children followed for extended periods of time have been reported to show further resolution of lipodystrophy [36] .
In this trial, we did not observe improvements in lipid or triglyceride levels after the substitution of abacavir for stavudine. This result is somewhat surprising, because stavudine has been found to raise triglyceride levels [37] , and raised triglyceride levels have been found to occur in conjunction with lipodystrophy [9, 38] . Studies of stavudine dose reductions have observed declines in triglyceride levels [39, 40] . In contrast, we observed a transient increase in LDL levels with abacavir, but by the end of the study, the levels returned to those seen among children who remained on stavudine. The duration of follow-up might have been too short to observe the benefits of abacavir, or the adverse effects of LPV/r on the children's lipid profile [38, 41, 42] might have masked any benefits of abacavir. Children randomly assigned to stavudine-containing regimens (together with lamivudine and efavirenz or nevirapine) in the CHAPAS-3 trial did not differ in terms of lipid profiles when compared with those randomly assigned to take zidovudine or an abacavir-containing regimen [31] .
In this trial, there was no evidence of inferior viral efficacy of abacavir. These results are consistent with those of a recent large trial in children [31] . Programmatic data from South Africa, including from our site, reported virological outcomes in children initiated on abacavir-containing first-line regimens that were worse than those initiated on stavudine-containing regimens in earlier eras [19, 20] . The discrepant results might have been attributable to inherent differences between clinical trial conditions and routine clinical care, the facts that the children in the current trial were virally suppressed before random assignment and of an older age, or non-drug-related factors explaining the previously reported temporal trends in the programmatic data. Our data also reveal reassuring long-term viral load results after switching 1 drug in a stable drug regimen for toxicity purposes, which confirms the utility of this often-used clinical practice.
Stavudine is a highly efficacious antiretroviral drug when used as part of ART in the treatment of pediatric HIV, but it has been phased out because of toxicity concerns ( [20, 43] . Our results reveal that substitution of abacavir for stavudine in virally suppressed children reduced clinical signs of lipodystrophy and led to reductions in objectively measured central adiposity and increases in leg fat. Our trial has provided randomized clinical trial data that support the benefit of abacavir over stavudine in reducing the development of lipodystrophy in children.
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Notes
